Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant and adjuvant chemotherapy versus neoadjuvant chemoradiation for oesophageal and oesophago-gastric junction adenocarcinoma
ISRCTN60280514Phase 3Completed
- Sponsor
- Cancer Trials Ireland
- Start
- Mar 2015
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of epirubicin, cisplatin, capecitabine, fluorouracil, oxaliplatin and 2 more in adenocarcinoma of the lower esophagus and gastroesophageal adenocarcinoma (2 arms), sponsored by Cancer Trials Ireland. Primary endpoint: Overall survival at 1, 2, and 3 years. Started Mar 2015; status: completed.
02
Drugs
epirubicincisplatincapecitabinefluorouraciloxaliplatin
03
Conditions
adenocarcinoma of the lower esophagusgastroesophageal adenocarcinoma
Beyond the preview
Go deeper on ISRCTN60280514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN60280514.